All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Many therapies for myeloproliferative neoplasms (MPN) address symptom improvement without a focus on reduction in tumor size.1 Tamoxifen, a selective estrogen receptor modulator, has been shown to induce apoptosis in multipotent hematopoietic progenitors whilst sparing normal hematopoietic stem cells; therefore, it is under investigation to target tumor size in patients with stable MPN and without previous thrombotic events.1
Below, we summarize the phase II TAMARIN study (EudraCT 2015-005497-38) investigating tamoxifen in patients with stable MPN; no prior thrombotic events; and mutated JAK2V617F, CALRins5, or CALRdel52 peripheral blood allele burden ≥20%.
The baseline characteristics are shown in Table 1.
Table 1. Baseline patient characteristics*
Characteristics, % (unless otherwise specified) |
Patients |
Mean age, years |
66.3 |
Sex |
|
Male |
71.1 |
Female |
28.9 |
Disease subtype |
|
Essential thrombocythemia |
36.8 |
Primary myelofibrosis |
15.8 |
Post-essential thrombocythemia myelofibrosis |
5.3 |
Polycythemia vera |
28.9 |
Post-polycythemia vera myelofibrosis |
13.2 |
*Adapted from Fang, et al.1 |
The safety profile was manageable and four serious adverse events (SAE) were reported:
Tamoxifen was shown to reduce mutant allele burden in a subset of MPN patients who could be identified by hematopoietic stem cell transcriptomic signature before treatment. The primary endpoint (≥50% decrease in mutant allele burden in peripheral blood at 24 weeks) of this phase II study was met and observed in ≥3 patients. These findings advocate for future clinical studies to test the effectiveness of other selective estrogen receptor modulators in MPN, specifically the Janus kinase 2-signaling pathway.
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox